Potential effect of new (E)‐4‐hydroxy ‐N'‐(1‐(7‐hydroxy‐2‐oxo‐2H‐chromen‐3‐yl) ethylidene) benzohydrazide against acute myocardial infarction: Haemodynamic, biochemical and histological studies. (28th September 2020)

• Record Type: Journal Article
• Authors: Mnafgui, Kais; Khdhiri, Emna; Hajji, Raouf; Feriani, Anouar; Ivan da Silva, Francisco; Laíres da Silva Santos, Antônia; Tlili, Abir; Mlayeh, Souhail; Bouzidi, Moncef; Ammar, Houcine; Abid, Souhir
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 48:Number 1(2021)
• Page Start: 107
• Page End: 120
• Publication Date: 2020-09-28
• Subjects: coumarin -- dyslipidaemia -- molecular docking -- myocardial infarction -- oxidative stress -- protein disulphide isomerase; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.13397
• Languages: English
• ISSNs: 0305-1870

Abstract

Abstract: This study aimed to explore the cardioprotective effect of new synthesized coumarin (E)‐4‐hydroxy‐N'‐(1‐(7‐hydroxy‐2‐oxo‐2H‐chromen‐3‐yl) ethylidene) benzohydrazide denoted (Hyd.Cou) against myocardial infarction disorders. Male Wistar rats were divided into four groups; Control, isoproterenol (ISO), ISO + Acenocoumarol (Ac) and ISO + Hyd.Cou. Results showed that the ISO group exhibited serious alteration in EGC pattern, significant heart hypertrophy (+33%), haemodynamic disturbance and increase in plasma rate of CK‐MB, LDH and troponin‐T by 44, 53, and 170%, respectively, as compared to Control. Moreover, isoproterenol induced a rise in plasma angiotensin‐converting enzyme activity (ACE) by 49%, dyslipidaemia, and increased thiobarbituric acid‐reactive substances (TBARS) by 117% associated with decrease in the activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) by 46% and 58%, respectively in myocardium. Interestingly, the molecular docking calculation demonstrated strong interactions of Hyd.Cou with the receptors of the protein disulphide isomerase (PDI) which could highlight the antithrombotic effect. Moreover, Hyd.Cou improved plasma cardiac dysfunction biomarkers, mitigated the ventricle remodelling process and alleviated heart oxidative stress damage. Overall, Hyd.Cou prevented the heart from the remodelling process through inhibition of ACE activity and oxidative stress improvement. Abstract : The novel Hyd.Cou attenuates the cardiac remodelling process through inhibition of ACE activity and oxidative stress improvement.